Activated Her3 As A Marker For Predicting Therapeutic Efficacy

Patent No. EP2097754 (titled "Activated Her3 As A Marker For Predicting Therapeutic Efficacy") was filed by Daiichi Sankyo Europe on Nov 28, 2007. The application was issued on Jan 24, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
F HOFFMANN LA ROCHEOct 1, 2015GREEN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2097754

DAIICHI SANKYO EUROPE
Application Number
EP07846863A
Filing Date
Nov 28, 2007
Status
Patent Maintained As Amended
Dec 22, 2017
Publication Date
Jan 24, 2018